Skip to main content
Lewy body dementia drug trial halted in face of negative results

A trial of intepirdine was halted after the drug appeared to worsen cognition and motor control in patients with dementia with Lewy bodies. "Based on the totality of intepirdine data to date, there is no evidence to support its further development," said David Hung, chief executive of Swiss biotech Axovant, which developed the treatment.

Full Story: